Product image of Ilinpru Combi (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Ilinpru Combi

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Ilinpru Combi (Metformin Hydrochloride, Linagliptin)

Metformin Hydrochloride and Linagliptin, the active ingredients in Ilinpru Combi, are a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. They treat type 2 diabetes mellitus in adults by improving blood glucose control.
GNH India supplies Ilinpru Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ilinpru Combi combines metformin and linagliptin to manage hyperglycemia in type 2 diabetes mellitus.
  • Type 2 diabetes mellitus: improves glycemic control when used with diet and exercise.
  • Inadequate control with metformin alone: provides additional glucose‑lowering effect.
  • Patients intolerant to sulfonylureas: offers an alternative mechanism of action.
  • Combination therapy: synergistic effect with other antidiabetic agents.
  • Adjunct to lifestyle modification: supports overall metabolic management.

How It Works

  • Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while linagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin levels that promote glucose‑dependent insulin secretion and suppress glucagon release, together producing improved blood glucose regulation.

Side Effects

Ilinpru Combi may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Headache: mild to moderate intensity.
  • Dizziness: transient episodes, especially after dose initiation.
  • Upper respiratory symptoms: mild cough or sore throat.
  • Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

  • Lactic acidosis: rare but potentially fatal metabolic disturbance.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: acute inflammation of the pancreas.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.

Precautions & Warnings

  • Before prescribing Ilinpru Combi, clinicians should consider several safety aspects.
  • Renal function monitoring: assess creatinine clearance before initiation and periodically.
  • Hepatic function assessment: avoid use in patients with severe hepatic impairment.
  • Elderly patients: start at lower doses and monitor for hypoglycemia.
  • Concurrent hypoglycemic agents: adjust doses to reduce risk of low blood sugar.
  • Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed.
  • Store at room temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Ilinpru Combi can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; discontinue metformin temporarily.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): increase linagliptin exposure.
  • Rifampicin: reduces linagliptin plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Sulfonylureas: heightened risk of hypoglycemia; dose adjustment may be needed.
  • Diuretics: may affect renal clearance of metformin.
  • NSAIDs: can impair renal function, increasing metformin accumulation.
  • ACE inhibitors/ARBs: monitor renal function and potassium levels.

Frequently Asked Questions

Ilinpru Combi is an oral antidiabetic medication that combines metformin and linagliptin to improve blood glucose control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

Metformin reduces hepatic glucose production and increases peripheral insulin sensitivity, helping lower fasting and post‑prandial blood sugar levels without stimulating insulin secretion.

The specific dose of Ilinpru Combi is determined by the prescribing clinician based on the patient’s individual clinical profile, renal function, and response to therapy. Patients should follow the prescriber’s instructions precisely.

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy agents, the metformin‑linagliptin combination offers complementary mechanisms—metformin improves insulin sensitivity while linagliptin enhances insulin secretion—resulting in greater HbA1c reduction and a lower risk of hypoglycemia than sulfonylureas.

Store Ilinpru Combi at room temperature, below 25 °C, in the original blister pack or container, protecting it from moisture, direct sunlight, and excessive heat to maintain product stability.

Ilinpru Combi is taken orally, usually once daily with or after a meal, as directed by the prescriber. Swallow the tablet whole with water; do not crush or chew unless specifically instructed.

The most serious risks include lactic acidosis (rare but life‑threatening), severe hypoglycemia when combined with other glucose‑lowering agents, and acute pancreatitis. Patients should seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, or signs of low blood sugar.

Ilinpru Combi is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), severe hepatic disease, known hypersensitivity to metformin or linagliptin, and in those with a history of lactic acidosis. It should also be avoided in patients receiving iodinated contrast agents without appropriate discontinuation of metformin.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT